MedPath

This study is to survey on venous thromboembolism risk in cancer patients (lung or colorectal) who were about to start a new chemotherapy regimen.

Not Applicable
Completed
Conditions
Health Condition 1: null- Colorectal or Lung (SCLC or NSCLC) cancerHealth Condition 2: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Registration Number
CTRI/2013/02/003380
Lead Sponsor
Sanofi Synthelabo India Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
4300
Inclusion Criteria

Patients with:

•colorectal or lung (SCLC or NSCLC) cancer, cytologically or histologically confirmed,

•metastatic or locally advanced,

•and about to start a new chemotherapy

•Age >= 18 years

•Written informed consent

Exclusion Criteria

Patients on:

•Current or anticipated anticoagulant use with exception of use to maintain patency of central venous catheter only.

•Life expectancy < 4 months

•Patients participating or planned to be enrolled in clinical trials with blinded study therapy

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
â?¢To establish a risk score model predicting VTE in patients starting new chemotherapy for locally advanced or metastastic cancer (lung or colorectal) at Month-4 <br/ ><br>â?¢To assess risk factors for VTE specific to each type of cancer at Month-4 <br/ ><br>Timepoint: Month 4
Secondary Outcome Measures
NameTimeMethod
â?¢Incidence of proven VTE (including symptomatic and incidental DVT, PE, catheter thrombosis, visceral thrombosis) <br/ ><br>â?¢Arterial thrombosis (ischemic stroke, MI, acute PAD) <br/ ><br>â?¢Superficial venous thrombosis <br/ ><br>â?¢All Deaths (including VTE-related deaths) <br/ ><br>â?¢VTE treatment (prevention, curative) <br/ ><br>â?¢Bleeding events and thombocytopenia <br/ ><br>â?¢Cancer outcomes (response, stable, progression) <br/ ><br>Healthcare resources consumption <br/ ><br>Timepoint: Month 4
© Copyright 2025. All Rights Reserved by MedPath